Serina Therapeutics, Inc. (SER) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Serina Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Manufacturing
Prev close 2.40 · gapped below the open, never looked back. High/low 2.34 at 1:30 pm ET, 2.33 at 2:00 pm ET.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
No peer readings for Serina Therapeutics, Inc. yet.
tall tick = annual report · 1 on record
27 managers report a position worth $2.7M between them, and 2 of them hold 80% of it.
SER (Serina Therapeutics, Inc.) has 0 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.65%, in healthcare.